^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
GDT002
i
Other names: GDT002, GDT-002, TEG002, autologous T cells transduced with a specific γδTCR, TEG 002
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Century Therap
Drug class:
γδ TCR modulator
Related drugs:
2years
A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients (clinicaltrials.gov)
P1, N=26, Active, not recruiting, Gadeta B.V. | Recruiting --> Active, not recruiting
Enrollment closed
|
IL6 (Interleukin 6)
|
GDT002
3years
αβ-T Cells Engineered to Express γδ-T Cell Receptors Can Kill Neuroblastoma Organoids Independent of MHC-I Expression. (PubMed, J Pers Med)
Of note, efficacy of TEG002 treatment was superior to donor-matched untransduced αβ-T cells or endogenous γδ-T cells. Our data suggest that TEG002 may be a promising novel treatment option for a subset of neuroblastoma patients.
Journal • IO biomarker
|
IFNG (Interferon, gamma)
|
GDT002
over3years
A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients (clinicaltrials.gov)
P1, N=26, Recruiting, Gadeta B.V. | Initiation date: Feb 2021 --> May 2021
Clinical • Trial initiation date
|
IL6 (Interleukin 6)
|
GDT002
almost4years
A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients (clinicaltrials.gov)
P1, N=26, Recruiting, Gadeta B.V. | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
IL6 (Interleukin 6)
|
GDT002
almost4years
A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients (clinicaltrials.gov)
P1, N=26, Not yet recruiting, Gadeta B.V.
Clinical • New P1 trial
|
IL6 (Interleukin 6)
|
GDT002
Share via
